Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil

Journal of Infection in Developing Countries

Volumn 8, Issue 8, 2014, Pages 1037-1043

  Favalessa, Olivia Cometti ^a   de Paula, Daphine Ariadne Jesus ^a   Dutra, Valéria ^a   Nakazato, Luciano ^a   Tadano, Tomoko ^b   Lazera, Márcia dos Santos ^c   Wanke, Bodo ^c   Trilles, Luciana ^c   Walderez Szeszs, Maria ^d   Silva, Dayane ^d   Hahn, Rosane Christine ^a,b  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Antifungal drugs; Cryptococcus complex; Cryptococosis

Indexed keywords

ANTIFUNGAL AGENT; FUNGAL DNA;

ADULT; AGED; ANIMAL; BRAZIL; CHILD; CLASSIFICATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTIFUNGAL AGENTS; BRAZIL; CHILD; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DNA, FUNGAL; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; YOUNG ADULT;

EID: 84906043312     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.4446     Document Type: Article

References (53)

1. Kwon-Chung KJ, Varma SA (2006) Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 6: 574-587.
2. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-Chung J (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47: 561-570.
3. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50: 291-322.
4. Sajadi MM, Roddy KM, Chan-Tack KM, and Forrest GN (2009) Risk factors for mortality from primary cryptococcosis in patients with HIV. Postgrad Med 121: 107-113.
5. Fernandes OFL, Costa TR, Costa MR, Soares AJ, Pereira AJSC, Silva MR (2000) Cryptococcus neoformans isolados de pacientes com AIDS. Rev Soc Bras Med Trop 33: 75-78.
6. Nishikawa MM, Lazera MS, Barbosa GG, Trilles L, Balassiano BR, Macedo RC, Bezerra CC, Pérez MA, Cardarelli P, Wanke B (2003) Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. J Clin Microbiol 41: 73-77.
7. Lin X, Heitman J (2006) The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 60: 69-105.
8. Passoni LFC, Wanke B, Nishikawa MM, Lazera MS (1998) Cryptococcus neoformans isolated from human dwellings in Rio de Janeiro,Brazil: an analysis of the domestic environment of AIDS patients with and without cryptococcosis. Med Mycol 36: 305-311.
9. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, MacDougall L, Boekhout T, Kwon-Chung KJ, Meyer W (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101:17258-17263.
10. Murthy JMK (2007) Fungal infections of the central nervous system: The clinical syndromes. Neurol India 55: 221-225.
11. Chen S, Sorrel Tl, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, and Byth K (2000) Epidemiology and host-and variety dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 31: 499-508.
12. Morgan J, McCarthy KM, Gould S, Fan K, Arthington-Skaggs B, Iqbal N, Stamey K, Hajjeh RA, Brandt ME, and the Gauteng (2006) Cryptococcal Surveillance Initiative Group. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 43: 1077-1080.
13. Jain NBL, Wickes BL, Keller SM, Fu J, Casadevall A, Jain P, Ragan MA, Banerjee U, Fries BC (2005) Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol 43: 5733-5742.
14. Meyer W and Trilles L. Genotyping of the Cryptococcus neoformans/Cryptococcus gattii Species Complex. Australian Biochemist 2010 (41); 12-15.
15. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CH, Boekhout T (2012) Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis. 18: 1618-16124.
16. Favalessa OC, Ribeiro LC, Tadano T, Fontes CJF, Dias FB, Coelho BPA, Hahn RC (2009) Primeira descrição da caracterização fenotípica e susceptibilidade in vitro a drogas de leveduras do gênero Cryptococcus spp isoladas de pacientes HIV positivos e negativos, Estado de Mato Grosso. Rev Soc Bras Med Trop 42: 661-665.
17. Matsumoto MT, Fusco-Almeida AM, Baeza LC, Melhem MSC, Mendes-Giannini MJS (2007) Genotyping, serotyping and determination of mating-type of cryptococcus neoformans clinical isolates from São Paulo State, Brazil. Rev Inst Med Trop S Paulo 49: 41-47.
18. Casali AK, Goulart L, Rosa e Silva LK, Ribeiro AM, Amaral AA, Alves SH, Schrank A, Meyer W, Vainstein MH (2003) Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res 3: 405-415.
19. Matos CS, Andrade NS, Oliveira NS, Barros TF (2012) Microbiological characteristics of clinical isolates of cryptococcus spp in Bahia, Brazil: Molecular Types and antifungal susceptibilities. Eur J Clin Microbiol Infect 31: 1647-1652.
20. Souza LKH, Souza-Junior AH, Costa CR, Fagnello J, Vainstein MH, Chagas ALB, Souza ACM, Silva MRR (2009) Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil. Mycoses 53: 62-67.
21. Santos WRA, Meyer W, Wanke B, Costa SPSE, Trilles L, Nascimento JLM, Medeiros R, Morales BP, Bezerra Cde C, Macêdo RC, Ferreira SO, Barbosa GG, Perez MA, Nishikawa MM, Lazéra Mdos S (2008) Primary endemic Cryptococcosis gattii by molecular type VGII in the state of Pará, Brazil. Mem Inst Oswaldo Cruz 103: 813-818.
22. Correa MP, Oliveira EC, Duarte RR, Pardal PP, Oliveira FM, Severo LC (1999) Cryptococcosis in children in the state of Pará, Brazil. Rev Soc Bras Med Trop 32: 505-508.
23. Moretti ML, Resende MR, Lazéra MS, Colombo AL, Shikanai-Yasuda MA (2008) [Guidelines in cryptococcosis-2008]. Rev Soc Bras Med Trop 41: 524-544.
24. Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, Currie BJ, Hajkowicz K, Heath CH, Kidd S, McBride WJ, Meyer W, Murray R, Playford EG, Sorrell TC; Australia and New Zealand Mycoses Interest Group (ANZMIG) Cryptococcus Study (2013) Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis 57: 543-515
25. Aoki FH, Imai T, Tanaka R, Mikami Y, Taguchi H, Nishimura NF, Nishimura K, Miyaji M, Schreiber AZ, Branchini ML (1999) New PCR primer pairs specific for Cryptococcus neoformans serotype A or B prepared on the basis of random amplified polymorphic DNA fingerprint pattern analyses. J Clin Microbiol 37: 315-20.
26. Horta JA, Staats CC, Casali AK, Ribeiro AM, Schrank IS, Schrank A, Vainstein MH (2002) Epidemiological aspects of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. Med Mycol, 40: 565-571.
27. Del Poeta M, Toffaletti DL, Rude TH, Dykstra CC, Heitman J, Perfect JR (1999) Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target Genetics 152: 167-78.
28. Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E, Group I.C.S (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189-195.
29. Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
30. Nguyen MH, Yu CY (1998) In vitro comparative efficacy of voriconazole and itraconazole against fluconazole susceptible and resistant Cryptococcus neoformans isolates. Antimicrobial Agents Chemother 42: 471-472.
31. Lozano-Chiu MVL, Paetznick MA, Gannoum, Rex JH (1998) Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologycs. J Clin Microbiol 36: 2817-2822.
32. De Bedout C, Ordóñez N, Gómez BL, Rodríguez MC, Restrepo A, Castañeda E (1999) In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev Iberoam Micol 16: 36-39.
33. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D (1998) Antifungal drug resistance in pathogenic fungi. Med Mycol 36(1):119-128.
34. Meyer W and Trilles L (2010) Genotyping of the Cryptococcus neoformans/Cryptococcus gattii Species Complex. Australian Biochemist 41:12-15.
35. Springer DJ and Chaturvedi V (2010) Projecting Global Occurrence of Cryptococcus gattii. Emerging Infectious Diseases 16: 14-20.
36. Trilles L, Lazéra MS, Wanke B, Oliveira RV, Barbosa GG, Nishikawa MM, Morales BP, Meyer W (2008) Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz 3: 455-462.
37. Silva PR, Rabelo RAS, Terra APS, Teixeira DNS (2008) Suscetibilidade a antifúngicos de variedades de Cryptococcus neoformans isoladas de pacientes em hospital universitário. Rev Soc Bras Med Trop 41: 158-162.
38. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, MacDougall L, Boekhout T, Kwon-Chung KJ, Meyer W (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 101:17258-17263.
39. Byrnes EJ, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chaturvedi V, Bildfell RJ, Bildfell RJ, May RC, Heitman J (2010) Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 6: e1000850.
40. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CH, Boekhout T (2012) Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis. 18: 1618-24.
41. Anzai MC, Takarara DT, Simi W B, Wanke B, Lazera M S, Trillles L, Nakasato L, Dutra V, de Paula DA, Hahn, RC (2013) Cryptococcus gattii in a Plathymenia reticulate reticulate hollow in a Cuiabá, Mato Grosso. Brazil. Mycoses. In press.
42. Martins LMS, Wanke B, Lazéra MS, Trilles L, Barbosa GG, Macedo RCL, Cavalcanti MAS, Eulálio KD, Castro JAF, Silva AS, Nascimento FF, Gouveia VA, Monte SJH (2008) Genotypes of Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococcosis in Teresina, Piauí (northeastern Brazil). Mem Inst Oswaldo Cruz 106: 725-730.
43. Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U (2003) Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother 52: 683-68.
44. Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H (2006) In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 49: 324-30.
45. Lia M, Liaob Y, Chena M, Pana W, Weng L (2012) Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China. Braz J Infect Dis 16: 175-179.
46. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y (2004) Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 54: 563-565.
47. Soares BM, Santos DA, Kohler LM, César GC, Carvalho IR, Martins MA, Cisalpin OS (2008) Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing. Rev Iberoam Micol 25: 242-245.
48. Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CHW, Boekhout T, Meis JF (2010) In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii Isolates. Antimicrob Agents Chemother 54: 5139-5145.
49. Chong HS, Dagg R, Malik R, Chen S, Carter D (2010) In Vitro Susceptibility of the Yeast Pathogen Cryptococcus to Fluconazole and Other Azoles Varies with Molecular Genotype. J Clin Microbiol 48: 4115-4120.
50. Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR for the Cryptococcus gattii Public Health Working Group (2010) Correlation of Genotype and In Vitro Susceptibilities of Cryptococcus gattii Strains from the Pacific Northwest of the United States. J Clin Microbiol 48: 539-544.
51. Thompson GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF (2009) Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agent Chemother 53: 309-311.
52. Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J (2012) Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 56: 5898-5906.
53. Souza LKH, Fernandes OFL, Kobayashi CCBA, Passos XS, Costa CR, Lemos JA, Souza-Júnior AH, Silva MRR (2005) Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia City, Goiás, Brazil. Rev Inst Med Trop S Paulo 47: 253-256.